Recently, a phase I trial demonstrated encouraging results of clinical activity of CAR-T cell immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in 11 patients with advanced BTC and pancreatic cancers [193]. Here, ERBB2 is linked to familial pancreatic carcinoma.